Journal of Law and Policy
Volume 12
Issue 2
SCIENCE FOR JUDGES II:
The Practice of Epidemiology and Administrative
Agency Created Science

Article 3

2004

Systematic Review of Medical Evidence
John P.A. Ioannidis

Follow this and additional works at: https://brooklynworks.brooklaw.edu/jlp
Recommended Citation
John P. Ioannidis, Systematic Review of Medical Evidence, 12 J. L. & Pol'y (2004).
Available at: https://brooklynworks.brooklaw.edu/jlp/vol12/iss2/3

This Article is brought to you for free and open access by the Law Journals at BrooklynWorks. It has been accepted for inclusion in Journal of Law and
Policy by an authorized editor of BrooklynWorks.

IOANNIDISLAUMACRO.DOC

4/23/2004 12:51 PM

SYSTEMATIC REVIEW OF MEDICAL
EVIDENCE
John P.A. Ioannidis, M.D. & Joseph Lau, M.D.*
I.

THE NEED FOR SYSTEMATIC REVIEWS OF MEDICAL EVIDENCE

Medical questions that arise in everyday clinical practice are
often complex. The fascinating advances of the basic biomedical
sciences of the last two decades, such as the mapping of the human
genome, have created a widespread notion in the general public
that medical knowledge is highly advanced, well founded,
scientifically documented, and exact. Despite considerable
progress, however, the clinical practice aspect of the medical
science has not reached the same level of exactness as the physical
sciences or even the basic biological sciences. The complexity of
the human organism and the unpredictable nature of interactions
between specific interventions and specific patients are difficult to
reduce to the simplicity of physical laws. Knowledge about
molecular and cellular mechanisms is enlightening, and animal
data are very useful for medical progress, but it cannot be taken for
granted that they will be readily translated to medical practice, let
alone to the care of individual patients. First, basic knowledge
from biological and animal systems must be verified in humans,
and evidence must be corroborated from the application of various
medical interventions in patients. Biological concepts must be
tested in large numbers of human subjects to reduce the level of
statistical uncertainty. Even when this is done, highly promising
findings of basic biological research often do not turn out to hold
* John P.A. Ioannidis, M.D. is Adjunct Professor of Medicine, Tufts
University. Joseph Lau, M.D. is Professor of Medicine, Institute for Clinical
Research and Health Policy Studies, Tufts-New England Medical Center.

509

IOANNIDISLAUMACRO.DOC

510

4/23/2004 12:51 PM

JOURNAL OF LAW AND POLICY

true in routine clinical settings.1
An outsider may expect decisions about the best medical action
in a specific setting, the alternatives, and whether some actions are
clearly inadequate or unacceptable, to be uncomplicated. Yet,
medical decisions often involve a large number of complex clinical
questions. Typically several decisions need to be made
concurrently or sequentially. This is most clear in the case of
hospitalized patients who have several medical problems that may
affect each other. These patients may already be receiving many
medications, and while each one of the medications may have been
tested alone in clinical studies, there may be limited knowledge on
their interactions. In addition, the clinical course of hospitalized
patients may be very fragile, and rapid changes in their conditions
may occur. The available background information for making
rapid decisions may vary, and it is not uncommon for even
experienced physicians to miss large parts of the diagnostic puzzle
or even the main diagnosis itself. For patients with highly complex
interrelated problems, there may be little instructive precedent in
the medical literature on how to handle similar cases with the same
combination of problems. For example, for a patient with
hypertension (increased blood pressure), there may be extensive
data available on similar cases, since one in five Americans has
high blood pressure.2 On the other hand, prior knowledge may be
more limited and more difficult to apply when someone also has
heart disease, diabetes mellitus, high cholesterol, osteoporosis,
liver dysfunction, kidney impairment, and is already taking several
medications.
Even for uncomplicated situations, medical decision-making
still can be quite challenging. For a healthy young woman who
1

See Despina G. Contopoulos-Ioannidis et. al., Translation of Highly
Promising Basic Science Research into Clinical Applications, 114 AM. J. MED.
477 (2003) (reporting that of 101 findings published in major basic science
journals from 1977 through 1982 where explicit promises were made for clinical
applications, only 5 of them had resulted in some licensed clinical use twenty
years later and only one of them had a considerable clinical impact).
2
See American Heart Association, High Blood Pressure Statistics, at
http://www.americanheart.org/presenter.jhtml?identifier=4621 (last visited
March 2, 2004).
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comes to a physician for a routine check-up, there are many
decisions to make. One of the many decisions may be whether to
offer mammography as a screen test for breast cancer. Screening
mammography has been recommended by several professional
organizations and government agencies and is widely deemed as
an effective means to reduce breast cancer mortality; yet, this
apparently straightforward recommendation is controversial, and
the evidence supporting this recommendation has been
challenged.3 As all medical tests suffer from unavoidable errors,
finding an abnormality on a mammogram does not necessarily
mean the woman has breast cancer. It is possible that the
abnormality may be a case of “false positive” results. False
positive results are inherent uncertainties in the ability of a test to
differentiate disease from non-disease conditions; even the best
tests are susceptible to false positive results, even when performed
carefully with state-of-the-art equipment. A false positive test can
lead down a path of undesirable outcomes as a consequence of
further testing and medical management. For example, a woman
who has a false positive mammogram suggesting abnormalities is a
candidate for a breast biopsy. While the risk of serious
complications resulting from a breast biopsy is low, it still carries
small risks of bleeding and infection, and it also creates anxiety in
the patient. For other potentially more dangerous tests like liver
biopsy, serious bleeding may lead to hospitalization. Hospital
admission may lead to other complications, such as acquiring an
infection while in the hospital. In all, every action in medicine has
to be carefully balanced for its potential benefits and risks,4 and it
is often difficult to take into account all the possible interactions
and developments in patients.
The complexity and uncertainty in medical decision-making
has shown that it is very important to utilize the best available
evidence in each case and to scrutinize the quality of the evidence

3

See, e.g., Peter C. Gotzsche & Ole Olsen, Is Screening for Breast Cancer
with Mammography Justifiable?, 255 LANCET 129 (2000).
4
For a discussion of approaches towards balancing risks against benefits,
see Paul P. Glasziou & Les Irwig, An Evidence Based Approach to
Individualising Treatment, 311 BRIT. MED. J. 1356 (1995).
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accumulated from past medical research. The questions are, where
should this evidence come from, and how should it be appraised
and synthesized to arrive at a most meaningful and seasoned
decision?
II. OVERVIEW OF THE HIERARCHY OF MEDICAL EVIDENCE
A. Expert Opinion
Medical practice and policy-making often relied on expert
opinions. Expert opinions may be offered as patient care
consultations, informal discussions among colleagues, lectures, or
in written forms as book chapters, review articles, or editorials. In
the last few decades, there has been an increasing recognition that
relying on expert opinion to make medical decision has significant
shortcomings. Analyses of medical review articles have shown that
coverage of the potentially relevant data by the authors is often
sketchy, anecdotal, and highly subjective or even biased.5 The
proposed recommendations may not represent the findings of the
actual data from medical studies, and sometimes the
recommendations may be in favor of totally ineffective therapies,
or against therapies that have been shown to be beneficial.6
The unbalanced reviews offered by experts should not be
surprising. In the current era of the information revolution, the
amount of medical information that is being generated is
staggering. Over a million biomedical articles are published in
international journals every year. Even an expert in a highly
5

The first major assessment of the deficiencies of the traditional review
article in the medical literature was published in 1987. See Cynthia D. Mulrow,
The Medical Review Article: State of the Science, 106 ANNALS INTERNAL MED.
485 (1987).
6
In 1992, it was shown that the best written documents based on expert
opinion often failed to follow what the true data suggested in the treatment of
acute myocardial infarction, and sometimes they even contradicted the data. See
Eliott M. Antman et. al., A Comparison of Results of Meta-analyses of
Randomized Control Trials and Recommendations of Clinical Experts.
Treatments for Myocardial Infarction, 268 J. AM. MED. ASS’N 240 (1992).
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specialized field would have to read many thousands of articles a
year to be certain that she is not missing essential information. The
variable quality of this information further adds to the problem,
since one needs to have considerable training in research
methodology and to spend a lot of time evaluating the strengths
and limitations of each study. Experts who are influential often are
excellent in their specialty, but they may lack formal training in
research methodologies and in critically reviewing the literature. In
addition, subjectivity is unavoidable. Finally, it is probably quite
common for experts to have some conflicts of interest, financial or
otherwise, or topics in which they have invested their careers or
reputations.7 The relative contribution of these reasons towards the
inadequacy of using experts alone for judging medical evidence is
unknown, and probably it varies from case to case. Given these
limitations, however, it is currently generally accepted that expert
opinion in the absence of data comprises the lowest level of
evidence in the hierarchy of medical evidence.8

7

The potential conflicts of experts have recently drawn considerable
attention. See, e.g., J. Abraham, The Science and Politics of Medicines Control,
26 DRUG SAFETY 135 (2003); Sheldon Krimsky et. al., Scientific Journals and
Their Authors’ Financial Interests: a Pilot Study, 67 PSYCHOTHERAPY &
PSYCHOSOMATICS 194 (1998); George N. Papanikolaou et. al., Reporting of
Conflicts of Interest in Guidelines of Preventive and Therapeutic Interventions,
1 B.M.C. MED. RES. METHODOLOGY 3 (2001).
8
There are several different scales for rating evidence. Simple three-tier
systems such as those used by the United States Preventive Services Task Force
are commonly adopted or modified. According to this scheme, level I evidence
corresponds to evidence obtained from at least one properly randomized
controlled trial; level II corresponds to evidence obtained from well-designed
controlled trials without randomization (II-1), well-designed cohort or casecontrol analytic studies, preferably from more than one center or research group
(II-2), or multiple time series with or without the intervention or uncontrolled
experiments with dramatic results (II-3); and level III corresponds to opinions of
respected authorities, based on clinical experience; descriptive studies and case
reports; or reports of expert committees. For a comprehensive review of
available systems to rate the medical evidence, see Suzanne West et. al., Systems
to Rate the Strength of Scientific Evidence, Agency for Healthcare Research and
Quality, Evidence report/Technology Assessment Number 47, Apr. 2002.
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B. Non-randomized Studies

There is wide consensus that the strength of the evidence in
medicine should depend on the amount, quality, and consistency of
the available data that has been generated from biomedical
research. The amount of data is important but far from sufficient.
The quality of the data is very important, since small studies that
are well designed may give more accurate conclusions than large
studies that have clear flaws in their design and execution. Finally,
for each medical question of interest many different studies may
have been conducted. It is thus important to be able to acquire a
synthesis of the available evidence and to examine the whole
picture emerging from the totality of the data. When all the
different studies on the same question agree, this consistency is
reassuring, while disagreements need to be probed and explained,
if possible. Exceptions to the rule are common in medicine.
1. Observational and Cross-Sectional Studies
The quality of medical studies is not straightforward to assess.
Based on theoretical considerations, however, some types of
studies are less susceptible to potential errors and biases compared
with others. Case-reports of single observations and series of cases
can provide useful information, but they lack a control comparison
and thus one can only see what has happened to one or several
patients without being able to tell what might have happened if a
different course of action had been employed. Therefore, such
observational studies without a control population are typically
considered to be superior to plain expert opinion in the absence of
data, but inferior to other types of study designs.9 The same largely
holds true of cross-sectional designs, where a population is studied
in terms of outcomes and candidate factors of interest and

9

There is an effort to improve the quality of case reports in the medical
literature and to upgrade their status based on the principles of evidence-based
medicine. See, e.g., MILOS JENICEK, CLINICAL CASE REPORTING IN EVIDENCEBASED MEDICINE, (2d ed. 2001); Jan P. Vandenbroucke, In Defense of Case
Reports and Case Series, 134 ANNALS INTERNAL MED. 330 (2001).
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associations are evaluated. In such studies, outcomes and candidate
factors associated with them are measured at the same time, so it is
not possible to tell where there is a causative relationship in the
absence of a temporal sequence.
2. Case-Control and Retrospective Cohort Studies
Case-control studies and retrospective cohort studies have the
advantage that both patients with an adverse outcome and those
without an outcome of interest are available and that these groups
can be compared in terms of various factors that may or may not
be associated with the outcomes. A temporal sequence of events is
available. Again, however, the detection of significant associations
on the basis of statistical tests does not guarantee clinical or
biological causality. Furthermore, there can be bias in the choice of
the control groups (subjects without the outcome of interest).
Finally, these studies are retrospective, in that they are based on
collecting information from the past, and such information may be
subject to major errors or problems from missing data since the
data has not been collected with a specific prospective plan in
mind.
3. Prospective Cohort Studies
Prospective cohort studies have a higher level in the hierarchy
of evidence. In this case, groups of people are followed into the
future and the potential association between various factors and
outcomes can be discerned over time. These studies by definition
may take a long time to conduct, and they are more expensive than
retrospective studies, but there is room for better data collection
according to pre-specified rules. Still, these studies suffer from the
limitation that people are not assigned randomly to having or not
having a specific factor, so there is considerable room for bias. For
example, one can compare patients who had a new aggressive type
of surgery against those who chose to have the old type of
operation. It is possible that patients and physicians who choose
the new aggressive type of intervention are those who have the
worst or more advanced disease and are desperate to try something
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new. If they fare worse than those who got the old type of
operation, this may be due simply to the fact they were at a worse
condition even before the operation. Conversely, the new operation
may be reserved only for patients who are in the best possible
condition if patients and physicians feel the risk of adverse events
may be too high for patients having any background problems. In
this case, the new operation may have superb outcomes only
because the most favorable patients were selected upfront. This
problem is known as confounding by indication. Confounding may
involve also a number of other known or unknown patient
characteristics beyond the severity of illness. Thus, for all semiexperimental studies (both prospective and retrospective cohort
studies and case-control studies), to arrive at a net effect of the
factor of interest, it is important to adjust the compared groups for
all possible imbalances that may exist between them. Adjustment
is rarely straightforward, however, and it is unlikely that all
potential imbalances between the compared groups can be
identified a priori and taken into account.10
4. Randomized Trials
The problem of confounding is avoided when randomized trials
are conducted. In randomized trials, subjects are divided into two
or more groups in a random fashion that guarantees that
imbalances between the compared groups are unlikely, and if
present, they are purely due to chance and likely to cancel
themselves out if a sufficiently large number of subjects can be
randomized. Randomized trials have been used for over fifty years
in medicine, and they are accepted as the reference standard for
assessing the efficacy of medical interventions with the least bias.11
Even within randomized trials, not all studies are the same.
Besides sample size, studies may differ on various aspects of study
10

For more details on semi-experimental studies, see KENNETH J.
ROTHMAN & SANDER GREENLAND, MODERN EPIDEMIOLOGY (1998).
11
Randomized trials are the perceived gold standard for evidence despite
their acknowledged limitations. See, e.g., Alejandro R. Jadad & Drummond
Rennie, The Randomized Controlled Trial Gets a Middle-Aged Checkup, 279 J.
AM. MED. ASS’N 319 (1998).
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design. These aspects include whether blinding is used or not; how
well randomization has been performed; whether the allocation
sequence has been adequately concealed or not; and whether
follow up and patient flow has been carefully examined, as far as
patients withdrawing from the assigned treatment are concerned.
There is considerable debate on whether these or other study
parameters may be affecting the results of the trials. Some
evidence suggests that poor quality studies may tend to inflate the
estimated efficacy of medical interventions.12 However, quality is
often hard to define and/or may be difficult to discern from
published medical reports because what is reported may not be an
accurate reflection of what actually happened during the trial.13
Thus in some cases, studies with poor quality characteristics may
actually show a smaller effect for an experimental intervention
than studies with good quality ratings.14 In the presence of quality
defects, the direction of bias in the results is often difficult to
determine.
Given this uncertainty, there is increasing understanding that
the quality of medical research needs to be improved and held at
high standards. For some medical fields, the overall feeling is that
the quality of research methods used has been lagging behind
acceptable standards. Several years ago, the editor of the Lancet
wrote an editorial where in the title he questioned whether surgical
trial research exists or is all just “comic opera.”15 Although this
12

See, e.g., Kenneth F. Schulz et. al., Empirical Evidence of Bias.
Dimensions of Methodological Quality Associated with Estimates of Treatment
Effects in Controlled Trials, 273 J. AM. MED. ASS’N 408 (1995) (finding that
lack of allocation concealment inflates the observed treatment effect by 40% and
lack of double-blinding inflates the treatment effect by about 20%). See also
Peter Juni et. al., Systematic Reviews in Health Care: Assessing the Quality of
Controlled Clinical Trials, 323 BRIT. MED. J. 42-46 (2001) (reviewing such
studies).
13
John P.A. Ioannidis & Joseph Lau, Can Quality of Clinical Trials and
Meta-analyses be Quantified?, 352 LANCET 590 (1998).
14
This has been demonstrated in studies of infectious disease-related
interventions by Ethan M. Balk et. al., Correlation of Quality Measures with
Estimates of Treatment Effect in Meta-analyses of Randomized Controlled
Trials, 287 J. AM. MED. ASS’N 2973 (2002).
15
Richard Horton, Surgical Research or Comic Opera: Questions, but Few
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may be an exaggeration, it reflects the difficulties in improving the
quality of medical research. One vein of effort has focused
attention on standardizing the reporting of the results of medical
studies in the peer-reviewed literature. Comprehensive checklists
that ensure all the important information is conveyed have been
developed and accepted for randomized trials.16 Efforts are
underway to develop and agree on similar standards for the
reporting of other types of studies.
III. DIVERSITY OF MEDICAL EVIDENCE
The hierarchy of evidence discussed above is not cut in stone.
For some types of important medical questions, some or all of
these types of study designs may not be equally applicable. For
example, in studying the effects of potentially harmful factors
(e.g., the harmful effects of radiation or smoking), it is unethical to
use randomized trials. Randomized trials may also be infeasible
when it is difficult to commit individuals to specific interventions,
e.g., making some behavioral or nutritional changes.17 To evaluate
the accuracy of diagnostic tests, a different type of study is
necessary, where people with and without the disease are subjected
to the diagnostic test of interest and a comparator reference
standard test to see whether the test under study comes close to the
reference standard.18 Medical prognosis also cannot be addressed
with randomized studies, but usually semi-experimental studies are

Answers, 347 LANCET 984 (1996).
16
The most widely adopted is the Consolidated Standards of Reporting
Trials (CONSORT). See Doug G. Altman et. al., The Revised CONSORT
Statement for Reporting Randomized Trials: Explanation and Elaboration, 134
ANNALS INTERNAL MED. 663 (2001).
17
This rationale is exemplified by positions held by Meir Stampfer. See
Meir Stampfer, Observational Epidemiology Is the Preferred Means of
Evaluating Effects of Behavioral and Lifestyle Modification, 18 CONTROLLED
CLINICAL TRIALS 494 (1997).
18
Discussion of diagnostic test studies is beyond the focus of this article.
For more details, see XIAO-HUA ZHOU, NANCY A. OBUCHOWSKI & DONNA K.
MCCLISH, STATISTICAL METHODS IN DIAGNOSTIC MEDICINE (2002).
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used.19 Moreover, even when several different designs can be
equally applied to a specific question, there is no guarantee that
studies using designs at a higher level in the hierarchy of evidence
are necessarily superior to studies using designs at a theoretically
lower level. Randomized trials sometimes disagree with the results
of semi-experimental and observational studies on the same
question,20 but this does not mean that in all such cases of
disagreements the randomized trials are correct and the
observational evidence is wrong. Since bias may interfere in all
kinds of medical studies, sometimes poorly-done randomized
studies may be more unreliable than well-done cohort studies.
Furthermore, random error may affect the results of any human
study; by chance the results of randomized trials may occasionally
be further away from the truth than the results of other studies.
Within the same study design, sample size is important to
consider, and larger studies are likely to be more definitive than
smaller ones. There is no certainty that they are always likely to be
more correct, though. Empirical evaluations have shown that small
studies disagree with larger studies about a quarter of the times
beyond what would be anticipated by chance alone. In these cases,
it is not straightforward to tell which one is right or whether both
small and larger studies provide different sides of the truth and
complementary evidence. Interestingly, it has also been found that
large trials (defined as studies with at least 1,000 patients) disagree
among themselves about as frequently as the discrepancy between

19

However, it is possible to evaluate whether the application of a
prognostic system improves patient outcomes in the long-term or the efficiency
and cost-benefit of the health system. The same holds true for the application of
diagnostic tests. Such applications and their effects may then be studied with
randomized trials.
20
See, e.g., John P.A. Ioannidis et. al., Comparison of Evidence of
Treatment Effects in Randomized and Nonrandomized Studies, 286 J. AM. MED.
ASS’N 821 (2001) (comparing large versus smaller trials); but see, e.g., John
Concato et. al., Randomized, Controlled Trials, Observational Studies and
Randomized, Controlled Trials, 342 NEW. ENG. J. MED. 1878 (2000) (offering a
dissenting view). For discrepancies between very large trials (also called
“megatrials”), see T.A. Furukawa et. al., Discrepancies among Megatrials, 53 J.
CLINICAL EPIDEMIOLOGY 1193 (2000).
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large trials and meta-analyses of small trials.21
In all, it is unavoidable that sometimes studies seemingly
addressing the same question may reach different results. There
could be many reasons for this variability. Studies are conducted
with different designs, at different settings, in different
populations, with different background management and treatment,
in different countries, at different time periods.22 All of these
factors, in addition to the play of chance, could contribute to
variability. The whole emerging picture may be quite confusing
when an effort is made to reach a final conclusion even by the
most well informed and experienced experts. The quantity of data,
although useful in assessing consistency, can be overwhelming.
Systematic reviews and meta-analyses can provide a transparent
framework in such situations to make sense of the disparate data.
IV. SYSTEMATIC REVIEWS AND META-ANALYSES
A systematic review is a comprehensive assessment of the
medical literature on a topic of interest using a priori specified
rules for the search, identification, and eligibility of the pertinent
studies and for the abstraction of relevant data.23 The systematic
nature of the process according to clear-cut rules differentiates a
21

Several empirical evaluations have been published on the rate and
reasons of disagreements between small and larger studies. See John P.A.
Ioannidis et. al., Issues in Comparisons between Meta-analyses and Large
Trials, 279 J. AM. MED. ASS’N 1089 (1998); Joseph C. Cappelleri et. al., Large
Trials vs Meta-analysis of Smaller Trials: How Do Their Results Compare?, 276
J. AM. MED. ASS’N 1332 (1996); Jose Villar et. al., Predictive Ability of Metaanalyses of Randomized Controlled Trials, 345 LANCET 772 (1995); Jacques
LeLorier et. al., Discrepancies between Meta-analyses and Subsequent Large
Randomized, Controlled Trials, 337 N. ENG. J. MED. 536 (1997); T. A.
Furukawa et al., Discrepancies among Megatrials, 53 J. CLIN. EPIDEMIOLOGY
1193 (2000).
22
Joseph Lau et. al., Summing up Evidence: One Answer Is Not Always
Enough, 351 LANCET 123 (1998).
23
Deborah J. Cook et. al., Systematic Reviews: Synthesis of Best Evidence
for Clinical Decisions, 126 ANNALS INTERNAL MED. 376 (1997); Cynthia D.
Mulrow et. al., Systematic Reviews: Critical Links in the Great Chain of
Evidence, 126 ANNALS INTERNAL MED. 389 (1997).
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systematic review from a traditional review authored by experts
without specific rules. Systematic reviews currently have assumed
a key place in the generation of recommendations for medical
practice and for clinical decision-making.24 An international
initiative such as the Cochrane Collaboration is aiming to conduct
systematic reviews to cover all major aspects of health care.25 As
of the fall of 2003, the Cochrane Library includes 1,754 completed
Cochrane reviews and 1,304 protocols for ongoing reviews. In
addition, there are 4,123 abstracts of completed systematic reviews
in medical journals, theses, and reports that have been included in
the Database of Abstracts of Reports of Effects (DARE), also a
part of the Cochrane Library.26 In the United States, the Agency
for Healthcare Research and Quality has designated 13 evidencebased practice centers to produce comprehensive evidence reports
and technology assessments on a variety of health care topics.27
Over 100 of these reports have been produced over the past six
years. These reports are based on systematic reviews of the
medical literature and analyses of relevant databases, and are used
by various government agencies and professional and health care
organizations.
Systematic reviews target upfront a precisely defined clinical
question or set of questions. Depending on the question and the
24

Lisa A. Bero & Alejandro R. Jadad, How Consumers and Policymakers
Can Use Systematic Reviews for Decision Making, 127 ANNALS INTERNAL MED.
37 (1997); Deborah J. Cook et. al., The Relation between Systematic Reviews
and Practice Guidelines, 127 ANNALS INTERNAL MED. 210 (1997).
25
See THE COCHRANE COLLABORATION, at http://www.cochrane.org (last
visited March 2, 2004); Lisa Bero & Drummond Reenie, The Cochrane
Collaboration: Preparing, Maintaining, and Disseminating Systematic Reviews
of the Effects of Health Care, 274 J. AM. MED. ASS’N 1935 (1995); Mike Clarke
& Peter Langhorne, Revisiting the Cochrane Collaboration: Meeting the
Challenge of Archie Cochrane—and Facing up to Some New Ones, 323 BRIT.
MED. J. 821 (2000).
26
See THE COCHRANE COLLABORATION, at http://www.cochrane.org (last
visited March 2, 2004) (access to the Cochrane Library is limited to those with a
subscription).
27
See AGENCY FOR HEALTHCARE RESEARCH & QUALITY, AHRQ PUB. NO.
03-P006, EVIDENCE-BASED PRACTICE CENTERS (2003), at http://www.ahrq.
gov/clinic/epc/.
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eligibility criteria that are considered appropriate for selecting
studies on the question(s), some systematic reviews may include a
large number of eligible studies, while others may systematically
scrutinize hundreds and thousands of references from the medical
literature, only to conclude that no eligible study exists that
directly addresses the question of interest.28 Systematic reviews
that identify such lack of evidence are still useful since they clearly
show the direction for designing new studies in a field where
evidence-based inferences are urgently needed. Even in the
presence of data, systematic reviews may often conclude that the
available evidence is insufficient, controversial, or inconclusive
and that further studies are needed. In other cases, systematic
reviews conclude that the available data from several studies is
consistent and conclusive.
Even in the presence of systematic methods for locating and
appraising evidence, a systematic review can hardly be conclusive
unless the collected data can be appropriately synthesized in a
quantitative fashion. A meta-analysis is a quantitative synthesis of
data from various sources addressing the same question; a
systematic review is a prerequisite to a good meta-analysis. Most
meta-analyses use statistical methods to combine data from
published studies, and the information is available at the level of
groups, e.g., the outcomes in patients in each compared group.
Such meta-analyses of group data or meta-analyses of the
published literature are basically retrospective designs and have
several limitations including using only data that are available.
Meta-analyses may also be designed prospectively to collect
necessary data as well as to improve the consistency of collected
data, i.e., with a plan to combine the results from several studies
that are to be conducted.29 Furthermore, meta-analyses may be
28

For example, a systematic search of studies that might yield information
on how to tell whether a very common condition, acute conjunctivitis, is due to
viruses or bacteria, found no good study that had assessed the utility of clinical
signs and symptoms for making this diagnosis. See Remco P. Rietveld et. al.,
Diagnostic Impact of Signs and Symptoms in Acute Infectious Conjunctivitis:
Systematic Literature Search, 327 BRIT. MED. J. 789 (2003).
29
For prospective meta-analysis may start with the construct of a study
registry that tries to capture all studies performed on a specific topic right from
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extended to use not only group data, but data from individual
patients. Such individual-level data meta-analyses collate
information from diverse pertinent studies with data on each
patient on the exposures and outcomes of interest as well as a set
of other parameters that may be considered to be of interest.30
Clearly, meta-analyses of individual-level data are more difficult to
conduct, and their performance must be justified by considering
whether they are likely to provide additional or far more exact
results compared to meta-analyses of group data.
A. Place of Systematic Reviews and Meta-analyses in Medical
Decision-Making
Most schemes of the hierarchy of evidence have accepted that
meta-analyses, especially those of randomized trials, are the
highest level of medical evidence.31 This is due to the fact that
meta-analyses may combine data from a large number of studies
and, given their systematic background, they have an objective
opportunity for quantifying effects and associations, finding out
whether the data are consistent, and in some cases, also quantifying
the extent of inconsistency and probing into potential reasons for
the existence of discrepancies between studies.
By definition, systematic reviews and meta-analyses are highly
focused research designs. They address a specific question or a few
questions, and it is unlikely that they can cover all the tangible and
intangible issues that are involved in decision making. There is
increasing appreciation that systematic reviews and meta-analyses
should try to cover aspects of both efficacy and safety when
medical interventions are involved. This is often very difficult to
do because the quality and quantity of available data to assess the
their beginning (at the time they are designed or launched).
30
For meta-analysis of individual-level data, see Leslie A. Stewart & M.K.
Parmar, Meta-analysis of the Literature or of Individual Patient Data: Is There
a Difference?, 341 LANCET 418 (1993); Leslie A. Stewart & Mike J. Clarke,
Practical Methodology of Meta-analyses (Overviews) Using Updated Individual
Patient-Data—Cochrane Working Group, 14 STATISTICS IN MED. 2067 (1995).
31
See, e.g., Robin Harbour & Juliet Miller, A New System for Grading
Recommendations in Evidence Based Guidelines, 323 BRIT. MED. J. 334 (2001).

IOANNIDISLAUMACRO.DOC

524

4/23/2004 12:51 PM

JOURNAL OF LAW AND POLICY

benefits and harms of medical interventions varies a great deal.32
Even if several aspects of a clinical problem can be covered by a
meta-analysis, it is unlikely that a final decision can be made
directly on the basis of such evidence. Decision-making may
involve other important parameters such as cost issues; the
availability of resources; the availability or lack thereof of
alternative interventions; utility ranking when several, diverse
outcomes are involved; priority setting and overall strategic design
in institutions or health care systems; and the subjective
preferences of the patient.
Thus systematic reviews and meta-analyses provide some
highly filtered and carefully analyzed information that needs to be
placed in a broader context. Although physicians are increasingly
educated in understanding these research tools, often the subtleties
of meta-analyses may go beyond the appreciation of many
practitioners and health care workers. However, the results and
inferences of meta-analyses may be used efficiently for generating
more easily interpretable clinical directives. Clinical practice
guidelines, for example, are documents that aim to distill
recommendations for important medical practice decision-making.
In the past, most guidelines suffered from the same problems as
expert reviews, since they were generated typically by one or
several experts without any particular attention to the scientific
basis of collecting, appraising, and synthesizing the available
evidence. Major deficiencies in the quality of guidelines, even
those published by top quality medical journals and reputable
specialist societies have recently been scrutinized.33 A robust

32

Luis Gabriel Cuervo & Mike Clarke, Balancing Benefits and Harms in
Health Care: We Need to Get Better Evidence about Harms, 327 BRIT. MED. J.
65 (2003).
33
Defects on guidelines have been identified on their development,
reporting, evidence base, and transparency. See, e.g., Roberto Grilli et. al.,
Practice Guidelines Developed by Specialty Societies: The Need for a Critical
Appraisal, 355 LANCET 103 (2000); T.M. Shaneyfelt et. al., Are Guidelines
Following Guidelines? The Methodological Quality of Clinical Practice
Guidelines in the Peer-Reviewed Medical Literature, 281 J. AM. MED. ASS’N
1900 (1999); Ioannis A. Giannakakis et. al., Citation of Randomized Evidence in
Support of Guidelines of Therapeutic and Preventive Interventions, 55 J.
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process must be set for producing high-quality guidelines. This
process includes the systematic appraisal of the available data and
a transparent procedure for reaching consensus among experts
involved in guideline development, clarity in the presentation of
alternative options, a balance of risks and benefits, editorial
independence, and rigorous standards for prompt updating to
include newly released research data that, in some cases, may
strengthen, modify, or invalidate prior beliefs.34
B. Cumulative Meta-analysis
In this regard, meta-analysis can be seen as an exercise of
updating the totality of available information over time. In
cumulative meta-analysis, studies on a given medical question are
ordered chronologically.35 The results of each study are added one
at a time in the order in which they appear. Cumulative metaanalysis provides a picture of evolving trends as medical evidence
accumulates. It is possible to examine whether evidence has
remained steady over time or major fluctuations have occurred
over time. For example, occasionally, initial studies suggested an
intervention may be highly effective, while subsequent studies may
show that the same intervention is totally ineffective. Such big
changes are infrequent when a large amount of evidence has
accumulated from large and/or several studies. In some cases,
however, changes were seen even when many early studies,
including large ones, had accumulated over time.
For example, several studies on the efficacy of intravenous
magnesium salts in acute myocardial infarction, including a study
CLINICAL EPIDEMIOLOGY 545 (2002).
34
A widely adopted checklist for appraising guidelines has been developed
by the AGREE Collaboration. See AGREE Collaboration, Development and
Validation of an International Appraisal Instrument for Assessing the Quality of
Clinical Practice Guidelines: the AGREE Project, 12 QUALITY & SAFETY
HEALTH CARE 18 (2003).
35
Joseph Lau et. al., Cumulative Meta-analysis of Therapeutic Trials for
Myocardial Infarction, 327 N. ENG. J. MED. 248 (1992); Joseph Lau et. al.,
Cumulative Meta-analysis of Clinical Trials Builds Evidence for Exemplary
Medical Care, 48 J. CLINICAL EPIDEMIOLOGY 45 (1995).
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of 2,300 patients, had clearly documented large, significant
reductions in the mortality risk with this inexpensive intervention.
A larger study of over 50,000 patients showed no effect at all,
however, and the same lack of efficacy was documented in a
subsequent study with over 6,000 patients.36 Thus,
recommendations on the use of this therapy would change
dramatically over time, based on the evolution of meta-analysis
results. The interpretation of this example is further complicated by
the fact that the standard of care of patients in these trials has
evolved considerably over time. Many of the patients in the later
trials were concurrently receiving other forms of effective
treatments, thus confounding the interpretation of the results.
Comparison of the older trials and the newer ones may no longer
be valid and the treatment being evaluated may no longer be
relevant, given the current standard of care.
In another example, several very large non-randomized studies
of over 10,000 subjects suggested that estrogen replacement is a
highly beneficial intervention for post-menopausal women with
strong protective effects against cardiovascular disease.
Nevertheless, a large randomized study showed clearly that there is
no cardiovascular protection and the overall balance of risks
against benefits makes estrogen replacement a highly unfavorable
course of action for women in this age group.37 In the case of
estrogen replacement, different study designs (observational vs.
randomized data) led to different conclusions, even though both
types of designs entailed very large numbers of subjects.

36

For more details on the magnesium controversy, see the report of the
latest relevant trial: Magnesium in Coronaries (MAGIC) Trial Investigators,
Early Administration of Intravenous Magnesium to High-Risk Patients with
Acute Myocardial Infarction in the Magnesium in Coronaries (MAGIC) Trial: A
Randomised Controlled Trial, 360 LANCET 1189 (2002). That report also alludes
to the prior evidence on this controversial topic.
37
The Women’s Health Initiative (WHI) trial was the pivotal study that
reversed prior beliefs on the indications of estrogen replacement in postmenopausal women. The study results have been published in a series of
manuscripts in the Journal of the American Medical Association in 2002 and
2003 and have been extensively commented on in the scientific and lay
literature.
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The cases where large changes have occurred in our
appreciation of the role of specific medical interventions are
probably the exception, rather than the rule. In most cases, medical
evidence does not change so much over time. Provided that they
are well conducted,38 systematic reviews and meta-analyses may
thus provide the scientific ground for trusting the adequacy of
medical actions or lack thereof in specific settings. Still, the
evolutionary, cumulative nature of medical evidence should be
kept in mind as a way of understanding that uncertainty about
medical actions is unlikely to disappear completely even with
large-scale evidence and well-conducted studies.
C. Methods of a Systematic Review
The general approach to conducting a systematic review
consists of the following steps:
• Formulate answerable research question(s)
• Define the systematic review (meta-analysis) protocol
(establish inclusion and exclusion criteria)
• Perform literature search
• Screen titles and abstracts of literature search results for
potentially relevant studies and retrieve full articles
• Evaluate full articles according to criteria
• Critically appraise articles that met criteria
• Extract data for analysis
• Perform meta-analyses and sensitivity analyses as
appropriate
• Interpret results
One of the most important tasks in conducting a systematic

38

The conduct of meta-analysis requires rigorous standards as that of any
good research. Guidelines have been developed for the reporting of metaanalyses. See, e.g., David Moher et. al., Improving the Quality of Reports of
Meta-analyses of Randomised Controlled Trials: The QUORUM Statement.
Quality of Reporting Meta-analyses, 354 LANCET 1896 (1999); Donna F. Stroup
et. al., Meta-analysis of Observational Studies in Epidemiology: A Proposal for
Reporting. Meta-analysis of Observational Studies in Epidemiology (MOOSE)
Group, 283 J. AM. MED. ASS’N 2008 (2000).
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review is defining the question of interest and its limits.39 This is
important, since reviews with similar target-questions may reach
different conclusions if they have important differences on how
exactly the questions of interest are defined. It is important to
clarify the interventions or associations of interest; what types of
studies are to be examined and why some specific types of studies
are to be selected or excluded; what types of people are eligible for
including in these studies; which clinical settings are eligible and
which ones are not; and also what electronic or other databases of
medical information are to be searched for identifying the relevant
studies.
Some subtle decisions may make a difference sometimes. For
example, should published studies only be included or should
abstracts be eligible as well?40 For a recently targeted topic of
interest, much of the pertinent literature may still be in abstract
form, but for long-standing medical questions this is rarely an
issue. Another problem is whether both English and foreignlanguage sources of evidence should be used. A tower of Babel
bias has been described according to which non-English speaking
scientists may publish their results in English language journals
when they find significant differences, while they may prefer
native language journals when their results show no significant
differences.41 Hopefully, the English language covers the
overwhelming majority of the current scientific literature, so in
most instances this problem is not a major issue, but exceptions
may occur. Moreover, a reverse tower of Babel bias has been
described; where all the Chinese and Russian language articles on
acupuncture published in local non-English journal have
significant results.42
39

Carl Counsell, Formulating Questions and Locating Primary Studies for
Inclusion in Systematic Reviews, 127 ANNALS INTERNAL MED. 380 (1997).
40
Maureen O. Meade & W.S. Richardson, Selecting and Appraising
Studies for a Systematic Review, 127 ANNALS INTERNAL MED. 531 (1997).
41
Matthias Egger et. al., Language Bias in Randomised Controlled Trials
Published in English and German, 350 LANCET 326 (1997).
42
Andrew Vickers et. al., Do Certain Countries Produce Only Positive
Results? A Systematic Review of Controlled Trials, 19 CONTROLLED CLINICAL
TRIALS 159 (1998).
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Other parameters that relate to the way the clinical question is
circumscribed may have an even greater impact on the conclusions
of a systematic review. Sometimes, a systematic review may have
very loose eligibility criteria and may include people who differ in
important aspects among themselves. In this case, one may
question whether the overall findings of the review may be
extrapolated equally to each type of people and settings. In other
situations, a systematic review may use very narrow eligibility
criteria. This would result in a more sharpened target-population
where the results would be pertinent, but at the cost of the potential
to generalize and with considerable loss of potentially useful
information.43
D. Methods of a Meta-analysis
These considerations affect also the interpretation of a metaanalysis, since the first step towards conducting a quantitative
synthesis of the data is typically the conduct of a systematic
review. However, in a meta-analysis there are additional
methodological issues that need to be decided and that may affect
the results and their interpretation. We will avoid mathematical
details in our presentation of the key issues, focusing on the
meaning of the key issues and the impact that they may have.
First, there exist a large number of statistical methods for
combining data across studies.44 Even though these methods may
seem to an outsider to be a source of potentially large diversity,
empirical evidence suggests this is not a major concern.45
43

For example, a large number of meta-analyses (at least 9 we are aware
of) have been conducted trying to evaluate whether it is better to administer
these drugs once a day or multiple times a day in terms of the potential to
damage the kidneys and their efficacy for treating infections. The number of
studies included in these meta-analyses has varied by more than 3-fold since the
eligibility criteria of the different teams conducting the meta-analyses were
different.
44
For a brief, non-technical overview, see Joseph Lau et. al., Quantitative
Synthesis in Systematic Reviews, 127 ANNALS INTERNAL MED. 820 (1997).
45
See, e.g., Jose Villar et. al., Meta-analyses in Systematic Reviews of
Randomized Controlled Trials in Perinatal Medicine: Comparison of Fixed and
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Moreover, as the field of meta-analysis has matured over time,
analytical approaches have become more standardized. The first
step usually is to evaluate whether there is any formal, statistically
significant heterogeneity (diversity) between the results of the
eligible studies included in the meta-analysis. The detection of
formal heterogeneity does not mean that something is wrong with
the data used in the meta-analysis, but it provides a hint that the
results of the constituent studies differ between themselves.
Between-study differences may exist either because of genuine
diversity or because of bias, or in some cases chance may have
played its role. Conversely, when the heterogeneity test is not
significant, one cannot rule out completely that genuine diversity
and/or bias may exist, especially when the number of studies is
limited and the test has limited power to identify existing
diversity.46
One commonly used approach in many meta-analyses is the
estimation of an overall effect (average). The average is not
obtained by simply summing up the data, since this may lead to
paradoxical results and erroneous conclusions. Instead, the results
of each study are given a weight inversely proportional to the
uncertainty (variance) of the results, which is a function of the total
number of study subjects and the number of events. Large studies
with little uncertainty in their estimates are thus given more weight
than smaller studies. In the presence of major differences in the
results of the various studies, even this weighting approach may be
inappropriate, since it assumes that all studies have different results
due to chance alone, something that seems unlikely in this setting.
Appropriate statistical models are available that also take into
account the extent of diversity in the study results in generating a
summary estimate.
In the presence of significant differences between studies, there
Random Effects Models, 20 STAT. MED. 3635 (2001).
46
Empirical evidence and technical considerations on heterogeneity are
covered by Julian Higgins et. al., Statistical Heterogeneity in Systematic
Reviews of Clinical Trials: A Cricial Appraisal of Guidelines and Practice, 7 J.
HEALTH SERVICES RES. & POL’Y 51 (2002); Eric Engels et. al., Heterogeneity
and Statistical Significant in Meta-analysis: An Empirical Study of 125 Metaanalyses, 19 STATISTICS IN MED. 1707 (2000).
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are several other methods that can be used in trying to explain and
understand this heterogeneity. Meta-regression methods try to
relate common characteristics with differences in the results across
several studies. These methods are helpful when there are a large
number of studies.47 The analyses are mostly exploratory and
generate results that usually would have to be validated in
subsequent research. Moreover, some of these analyses are subject
to the ecological fallacy (when inferences based on average
characteristics of a group are extrapolated and applied to
individuals who comprise the group).
Another approach is multivariate modeling, and this is feasible
in meta-analyses of individual-level data. In this case, for each
patient in each study, information is available on several different
characteristics. One can then test whether the results are affected or
modified in the presence of each of these characteristics or
combinations thereof. These analyses are also exploratory, but they
may help clarify why diversity exists in the results of various
studies. At the end of the analysis, it may be possible to identify
subgroups of people who are different in their responses to the
same medical intervention or who have different magnitudes of
benefit and/or risk in relationship to the same intervention.48
It has been debated whether it is better to have one single large
study rather than a meta-analysis of several smaller studies. Large
studies are useful, but for most medical questions of interest they
are never performed. Therefore, the constellation of several small
clinical studies may be all that is available. Even if large studies
have been done, it is not certain that their results would be more
reliable than the results of smaller studies. Most often, all studies,
big and small, offer complementary evidence on a question of
interest.

47

For more details on meta-regressions and their relationship to other
commonly used meta-analysis methods, see Sander Greenland, Invited
Commentary: A Critical Look at Some Popular Meta-analytic Methods, 140
AM. J. EPIDEMIOLOGY 290 (1994).
48
Thomas A. Trikalinos & John P.A. Ioannidis, Predictive Modeling and
Heterogeneity of Baseline Risk in Meta-analysis of Individual Patient Data, 54
J. CLINICAL EPIDEMIOLOGY 245 (2001).
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E. Other Considerations in Meta-analysis
1. The Relationship between Quality and Selection

As discussed earlier, the results of systematic reviews and
meta-analyses may be affected by how comprehensive the criteria
are for selecting the studies to be included. Sometimes criteria may
be set on the basis of the perceived quality of studies; studies
considered to be of poor quality may be excluded or studies of
perceived poor quality may be contrasted against those of high
quality. The quality and potential deficits thereof should be
assessed in each of the studies considered for inclusion in a metaanalysis. However, quality may often be difficult to quantify, and
the effect of poor quality on the results of a study may often be
unpredictable. Some investigators have suggested that more weight
should be given to the results of high-quality studies.49 This is a
problematic approach since the allocation of differential weight
does not correct the quality deficits and it is unknown whether it
leads the summary results closer to the truth. The detection of
quality defects is important to give insight about how to improve
future research in the field and to give a hint about the uncertainty
that may accompany the research findings, especially when poor
quality is documented. One may have to give less credibility to (or
even discount) the results of poorly designed research, even if the
conclusions seem to be strong and beyond dispute from a purely
statistical perspective.
2. Publication Bias
Another issue to be considered is the possibility of publication
bias. Publication bias reflects the fact that small studies with
“negative” results may not be published because investigators,
peer-reviewers, and/or editors don’t find them as interesting as
49

David Moher et. al., Does Quality of Reports of Randomised Trials Affect
Estimates of Intervention Efficacy Reported in Meta-analyses?, 352 LANCET 609
(1998).
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studies that find statistically significant results (“positive”
studies).50 The terms “positive” and “negative” are misnomers
since well designed and conducted studies should be important
sources of evidence regardless of what their results are. The
selection of “positive” studies may nevertheless lead to spurious
impressions when data are synthesized. Another possibility is time
lag bias,51 according to which studies with negative results may
eventually be published, but they take longer to do so, as compared
with those with “positive” results. Time lag bias will also result in
more favorable estimates of effects when early data are
synthesized and in diminishing effects as a more complete picture
emerges over time.52
Several tests have been developed that try to detect publication
bias. These tests basically examine whether small studies tend to
give different results as compared with larger ones; or they try to
investigate whether the results of a meta-analysis would change
under the assumption that certain “negative” studies are imputed to
have been lost and their putative results are added to the overall
calculations.53 Time lag bias may be examined by performing

50

Publication bias has been documented both for randomized trials and for
observational studies. See, e.g., Phillipa J. Easterbrook et. al., Publication Bias
in Clinical Research, 337 LANCET 867 (1991); Kay Dickerin et. al., Factors
Influencing Publication of Research Results: Follow-up of Applications
Submitted on Two Institutional Review Boards, 267 J. AM. MED. ASS’N 374
(1992).
51
John P.A. Ioannidis, Effect of the Statistical Significance of Results on
the Time to Completion and Publication of Randomized Efficacy Trials, 279 J.
AM. MED. ASS’N 281 (1998); Jerome M. Stern & R. John Simes, Publication
Bias: Evidence of Delayed Publication in a Cohort Study of Clinical Research
Projects, 315 BRIT. MED. J. 640 (1997).
52
John P.A. Ioannidis et. al., Recursive Cumulative Meta-analysis: A
Diagnostic for the Evolution of Total Randomized Evidence from Group and
Individual Patient Data, 52 J. CLINICAL EPIDEMIOLOGY 281 (1999).
53
Matthias Egger et. al., Bias in Meta-analysis Detected by a Simple,
Graphical Test, 315 BRIT. MED. J. 629 (1997); Alex J. Sutton et. al., Empirical
Assessment of Effect of Publication Bias on Meta-analyses, 320 BRIT. MED. J.
1574 (2000); Sue Duval & R. Tweedie, Trim and Fill: A Simple Funnel-PlotBased Method of Testing and Adjusting for Publication Bias in Meta-analysis,
56 BIOMETRICS 455 (2000).
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cumulative meta-analyses. One may notice whether the summary
results tend to change in the same direction over time, in particular
when there is an indication of continuously diminishing summary
effects. These tests have their limitations. Genuine heterogeneity
may also give the same picture as publication bias,54 but all these
tests may give signals that a simple grand mean approach may be
missing important parts of the picture of the evidence.
CONCLUSIONS AND LEGAL IMPLICATIONS
Medical evidence is complex; it is heterogeneous and of
variable quality. Interpreting medical evidence is difficult.
Evidence must be appraised in its totality using robust systematic
approaches. Quantitative methods are required to achieve a
synthesis of the data across an increasing number of studies of the
same topic. Evidence is cumulative and may change over time, as
more data accumulate. Moreover, evidence, even when derived
from well-conducted studies, is subject to biases that may stem
from factors that are unrelated to the excellent performance of
isolated single investigations. Meta-analysis offers a useful tool to
summarize evidence across many studies, identify heterogeneity,
search for possible explanations for the presence of this diversity,
and offer hints about the possibility of existing bias. Even the best
evidence and the best meta-analyses thereof are not sufficient for
medical decision-making. Most medical decisions are complex and
require a frame of interpretation. Physicians should try to use the
best tools to justify their actions in everyday health care.
Systematic reviews and meta-analyses as well as evidence-based
recommendations that stem from them are one means for
enhancing the certainty and confidence of physicians about their
actions and can be used to justify medical practice. However, they
also provide a measure of the uncertainty that lies behind these
54

See, e.g., Jonathan A. Sterne et. al., Publication and Related Bias in
Meta-analysis: Power of Statistical Tests and Prevalence in the Literature, 53 J.
CLINICAL EPIDEMIOLOGY 1119 (2000). Some of the most commonly used tests
may sometimes be difficult to interpret. See, e.g., J.L. Tang & J.L. Liu,
Misleading Funnel Plot for Detection of Bias in Meta-analysis, 53 J. CLINICAL
EPIDEMIOLOGY 477 (2000).
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actions.
From a legal perspective, it is important that judges and
lawyers become more familiar with the advent of these evidencebased tools. While judicial decisions may continue to seek expert
testimonies, such testimonies should be increasingly based on solid
scientific evidence rather than expert opinion. Typically, a judge or
a lawyer may find it difficult to probe behind an expert’s opinion
to evaluate or test the level of credibility based on concepts of best
available evidence. Experts in court are typically challenged and
accepted on the basis of their qualifications, conflicts of interest, or
biases, and not on the value of their opinions. However, it would
be useful to understand that the medical expert is only one part of
the long chain of the medical evidence, and that there often can be
considerable uncertainty behind expert statements.

